Related Experiment Video
Updated: Aug 9, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
Coronary endothelial vasodilator dysfunction: clinical relevance and therapeutic implications
1Department of Internal Medicine III, University of Freiburg.
Zeitschrift Fur Kardiologie
|January 1, 1994
Summary
Coronary endothelial dysfunction contributes to atherosclerosis and myocardial ischemia. Therapies like ACE-inhibitors may improve endothelial nitric oxide (NO) synthesis and coronary blood flow.
Area of Science:
- Cardiovascular Biology
- Vascular Medicine
- Pharmacology
Background:
- Endothelial dysfunction in epicardial and resistance coronary arteries is a key factor in coronary artery disease (CAD).
- Impaired endothelial function contributes to atherosclerosis and myocardial ischemia by disrupting the balance of oxygen supply and demand.
- Understanding the mechanisms of endothelial dysfunction is crucial for developing targeted therapies.
Purpose of the Study:
- To review the role of endothelial function and dysfunction in CAD.
- To explore therapeutic strategies for improving endothelial function.
- To present author's results on the impact of ACE-inhibitors on coronary endothelial function.
Main Methods:
- Review of existing literature on endothelial function in CAD.
- Analysis of humoral and neuronal factors affecting coronary vascular reactivity.
- Evaluation of the L-arginine/NO pathway in endothelial dysfunction.
- Assessment of therapeutic interventions, including L-arginine supplementation, antioxidants, and ACE-inhibitors.
Main Results:
- Coronary endothelial vasodilator dysfunction is fundamental to atherosclerosis development.
- Dysfunction of the endothelial L-arginine/NO pathway involves multiple mechanisms.
- ACE-inhibitors improve endothelial function by reducing vascular tone and increasing NO and prostacyclin production.
- Chronic ACE-inhibition demonstrated improved coronary blood flow response to acetylcholine.
Conclusions:
- Endothelial dysfunction plays a critical role in the clinical presentation of CAD.
- Targeting the L-arginine/NO pathway offers potential therapeutic benefits.
- ACE-inhibitors show promise in improving endothelial vasodilator function in coronary resistance vessels.
More Related Videos
08:42Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
Published on: October 22, 2014
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...